Business Context and Reporting Period
This Form 8-K is filed by Cyclacel Pharmaceuticals, Inc. (CYCC) on April 2, 2025, reporting events occurring on March 31, 2025, and April 2, 2025. The filing addresses significant changes in corporate governance, specifically the departure of officers and directors and the appointment of new independent directors. Additionally, the filing references a press release (Exhibit 99.1) announcing financial results for the fourth quarter ended December 31, 2024.
Key Financial Metrics
The filing text references a press release containing financial results for the fourth quarter ended December 31, 2024, but does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity within the body of this 8-K document. Investors must refer to the attached Exhibit 99.1 for detailed financial data.
Material Changes and Governance Updates
Resignations Delayed
- David Lazar (Co-Principal Financial Officer and Co-Principal Accounting Officer): Agreed to delay his resignation from March 31, 2025, until the filing of the Company's Form 10-K for the fiscal year ended December 31, 2024. The resignation will be automatically effective on that filing date.
- Avraham Ben-Tzvi and David Natan (Independent Directors): Agreed to delay their resignations from March 31, 2025, until the Form 10-K filing date.
- Reasoning: The resignations were not the result of any disagreement regarding operations, policies, or practices.
New Appointments
On April 2, 2025, coinciding with the effective date of the resignations, the Board appointed two new independent directors:
- Dr. Satis Waran Nair Krishnan: A Medical Doctor with experience in public health and dermatology in Malaysia and Ireland. Proficient in English, Russian, and Ukrainian.
- Ms. Inigo Angel Laurduraj: An accounting professional with 20 years of experience, including roles as Senior Accounting Manager at IOI Oleochemicals and Auditor at Moore Stephens. Holds an ACCA and a Bachelor's in Accounting.
Board Composition and Committees
Following these changes, the Board consists of five directors, three of whom are independent, satisfying Nasdaq Listing Rule 5605(b)(1). The new directors were assigned to the following committees:
- Audit Committee: Kwang Fock Chong (Chair), Inigo Angel Laurduraj, Dr. Satis Waran Nair Krishnan.
- Compensation and Organization Committee: Inigo Angel Laurduraj (Chair), Kwang Fock Chong, Dr. Satis Waran Nair Krishnan.
- Nominating and Governance Committee: Dr. Satis Waran Nair Krishnan (Chair), Kwang Fock Chong, Inigo Angel Laurduraj.
No compensation has been determined for the new directors yet; future compensation will align with Company practices for non-employee directors.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statements regarding risks and uncertainties that could cause actual results to differ from expectations. No specific financial guidance or outlook was provided in the text of this 8-K. The filing notes that the information in Item 2.02 (Results of Operations) is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated April 2, 2025) for specific Q4 2024 financial figures (revenue, net loss, cash position).
- Monitor the filing date of the Form 10-K for the fiscal year ended December 31, 2024, as this triggers the automatic resignation of David Lazar, Avraham Ben-Tzvi, and David Natan.
- Verify the Company's compliance with Nasdaq independence requirements following the board reshuffle.
- Check for any subsequent announcements regarding compensation packages for the newly appointed directors.